(VIANEWS) – Shares of DMS IMAGING (BEL 20: DMSIM.BR) fell by a staggering 32.43% in 21 sessions from €0.03 to €0.02 at 05:08 EST on Wednesday, following the last session’s downward trend. BEL 20 is rising 0.26% to €3,817.13, after three successive sessions in a row of gains.
About DMS IMAGING
DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.
Volume
Today’s last reported volume for DMS IMAGING is 86072 which is 96.82% below its average volume of 241739.
More news about DMS IMAGING (DMSIM.BR).
